Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 68 results.
User Information
Export Records
  1. 1.   TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function
  2. Alam, Muhammad S; Gaida, Matthias M; Witzel, Hagen R; Otsuka, Shizuka; Abbasi, Aamna; Guerin,Theresa; Abdelmaksoud, Abdalla; Wong, Nathan; Cam,Maggie; Kozlov,Serguei; Ashwell, Jonathan D
  3. Cell Reports. Medicine. 2024, Aug 19; 101696.
  1. 2.   The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells
  2. Chen, X.; Oppenheim, J. J.
  3. Immunology. 2011, Aug; 133(4): 426-433.
  1. 3.   Effect of North Bicyclo[3.1.0]hexane 2 '-Deoxy-pseudosugars on RNA Interference: A Novel Class of siRNA Modification
  2. Terrazas, M.; Ocampo, S. M.; Perales, J. C.; Marquez, V. E.; Eritja, R.
  3. Chembiochem. 2011, May; 12(7): 1056-1065.
  1. 4.   Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
  2. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L.
  3. Clinical Cancer Research. 2010, Dec; 16(24): 6139-6149.
  1. 5.   Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis
  2. Sangaletti, S.; Tripodo, C.; Ratti, C.; Piconese, S.; Porcasi, R.; Salcedo, R.; Trinchieri, G.; Colombo, M. P.; Chiodoni, C.
  3. Cancer Research. 2010, Oct; 70(20): 7764-7775.
  1. 6.   Downregulation of Programmed Cell Death 4 by Inflammatory Conditions Contributes to the Generation of the Tumor Promoting Microenvironment
  2. Yasuda, M.; Schmid, T.; Rubsamen, D.; Colburn, N. H.; Irie, K.; Murakami, A.
  3. Molecular Carcinogenesis. 2010, Sep; 49(9): 837-848.
  1. 7.   Effect of Host Genetics on Incidence of HIV Neuroretinal Disorder in Patients With AIDS
  2. Sezgin, E.; Hendrickson, S. L.; Jabs, D. A.; Van Natta, M. L.; Lewis, R. A.; Troyer, J. L.; O'Brien, S. J.; Grp, S. R.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2010, Aug; 54(4): 343-351.
  1. 8.   Human beta-Defensin 2 and 3 and Their Mouse Orthologs Induce Chemotaxis through Interaction with CCR2
  2. Rohrl, J.; Yang, D.; Oppenheim, J. J.; Hehlgans, T.
  3. Journal of Immunology. 2010, Jun; 184(12): 6688-6694.
  1. 9.   Transcription Factor E2F1 Suppresses Dendritic Cell Maturation
  2. Fang, F.; Wang, Y.; Li, R.; Zhao, Y.; Guo, Y.; Jiang, M.; Sun, J.; Ma, Y.; Ren, Z. J.; Tian, Z. G.; Wei, F.; Yang, D.; Xiao, W. H.
  3. Journal of Immunology. 2010, Jun; 184(11): 6084-6091.
  1. 10.   Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex
  2. Brooks, A. D.; Jacobsen, K. M.; Li, W. Q.; Shanker, A.; Sayers, T. J.
  3. Molecular Cancer Research. 2010, May; 8(5): 729-738.
  1. 11.   Accelerated thymic atrophy as a result of elevated homeostatic expression of the genes encoded by the TNF/lymphotoxin cytokine locus
  2. Liepinsh, D. J.; Kruglov, A. A.; Galimov, A. R.; Shakhov, A. N.; Shebzukhov, Y. V.; Kuchmiy, A. A.; Grivennikov, S. I.; Tumanov, A. V.; Drutskaya, M. S.; Feigenbaum, L.; Kuprash, D. V.; Nedospasov, S. A.
  3. European Journal of Immunology. 2009 39(10): 2906-2915.
  1. 12.   Expression of Interleukin-15 and Its Receptor on the Surface of Stimulated Human Umbilical Vein Endothelial Cells
  2. Liu, X. P.; Zuo, Y. M.; Zhang, W. N.; Yang, D. G.; Xiong, C. Y.; Zhang, X. Z.
  3. Journal of Huazhong University of Science and Technology-medical Sciences. 2009 29(5): 527-534.
  1. 13.   Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
  2. Sissung, T. M.; Thordardottir, S.; Gardner, E. R.; Figg, W. D.
  3. Anti-cancer agents in medicinal chemistry. 2009 9(10): 1058-1069.
  1. 14.   Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
  2. Weiss, J. M.; Back, T. C.; Scarzello, A. J.; Subleski, J. J.; Hall, V. L.; Stauffer, J. K.; Chen, X.; Micic, D.; Alderson, K.; Murphy, W. J.; Wiltrout, R. H.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2009 106(46): 19455-19460.
  1. 15.   Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Wine, J. W.; Elliott, P. J.; Yagita, H.; Takeda, K.; Smyth, M. J.; Murphy, W. J.; Sayers, T. J.
  3. Journal of the National Cancer Institute. 2008 100(9): 649-662.
  1. 16.   Thalidomide analogues as anticancer drugs
  2. Aragon-Ching, J. B.; Li, H. Q.; Gardner, E. R.; Figg, W. D.
  3. Recent Patents on Anti-Cancer Drug Discovery. 2007, Jun; 2(2): 167-174.
  1. 17.   Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia
  2. Wu, C. F.; Bi, X. L.; Yang, J. Y.; Zhan, J. Y.; Dong, Y. X.; Wang, J. H.; Wang, J. M.; Zhang, R. W.; Li, M.
  3. International Immunopharmacology. 2007, Mar; 7(3): 313-320.
  1. 18.   Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis
  2. Panchal, R. G.; Ruthel, G.; Brittingham, K. C.; Lane, D.; Kenny, T. A.; Gussio, R.; Lazo, J. S.; Bavari, S.
  3. Chemistry & Biology. 2007, Mar; 14(3): 245-255.
  1. 19.   Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study
  2. Purdue, M. P.; Lan, Q.; Kricker, A.; Grulich, A. E.; Vajdic, C. M.; Turner, J.; Whitby, D.; Chanock, S.; Rothman, N.; Armstrong, B. K.
  3. Carcinogenesis. 2007, Mar; 28(3): 704-712.
  1. 20.   Induction of the formyl peptide receptor 2 in microglia by IFN-gamma and synergy with CD40 ligand
  2. Chen, K. Q.; Iribarren, P.; Huang, J.; Zhang, L. Z.; Gong, W. H.; Cho, E. H.; Lockett, S.; Dunlop, N. M.; Wang, J. M.
  3. Journal of Immunology. 2007, Feb; 178(3): 1759-1766.
  1. 21.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 22.   The role of cytokine mRNA stability in the pathogenesis of autoimmune disease
  2. Seko, Y.; Cole, S.; Kasprzak, W.; Shapiro, B. A.; Ragheb, J. A.
  3. Autoimmunity Reviews. 2006, May; 5(5): 299-305.
  1. 23.   Suppression of p65 phosphorylation coincides with inhibition of I kappa B alpha polyubiquitination and degradation
  2. Hu, J.; Haseebuddin, M.; Young, M.; Colburn, N. H.
  3. Molecular Carcinogenesis. 2005, DEC; 44(4): 274-284.
  1. 24.   IL-4 inhibits the expression of mouse formyl peptide receptor 2, a receptor for amyloid beta(1-42), in a TNF-alpha-Activated microglia
  2. Iribarren, P.; Chen, K. Q.; Hu, J. Y.; Zhang, X.; Gong, W. H.; Wang, J. M.
  3. Journal of Immunology. 2005, NOV 1; 175(9): 6100-6106.
  1. 25.   Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
  2. Sun, K.; Wilkins, D. E. C.; Anver, M. R.; Sayers, T. J.; Panoskaltsis-Mortari, A.; Blazar, B. R.; Weiniak, L. A.; Murphy, W. J.
  3. Blood. 2005, NOV 1; 106(9): 3293-3299.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel